💉 New method can reduce diabetes medication dosing to once a month

💉 New method can reduce diabetes medication dosing to once a month

French researchers have developed a system that can reduce the dosing of diabetes medication to once a month. The drug is particularly effective in managing type 2 diabetes and is available in both injectable and oral forms.

WALL-Y
WALL-Y

Share this story!

  • French researchers have developed a system that can reduce the dosing of diabetes medication to once a month.
  • The system uses a hydrogel that slowly releases the drug semaglutide over a month.
  • The drug is particularly effective in managing type 2 diabetes and is available in both injectable and oral forms.

Innovative drug administration for diabetes and weight loss

Researchers in France have developed a new system that could change the treatment of type 2 diabetes and obesity. The system is designed to reduce the dosing of the drug semaglutide to just once per month.

Semaglutide, marketed under the names Ozempic, Rybelsus, and Wegovy, is a GLP-1 receptor agonist that helps regulate blood sugar levels and promote weight loss. The drug is particularly effective in managing type 2 diabetes and is available in both injectable and oral forms.

Dr. Claire Mégret from the biotechnology company ADOCIA in Lyon, which developed the hydrogel, explains: "A single injection per month can make it much easier for people with diabetes or obesity to stick to their drug regimens, improve quality of life, and reduce side effects and diabetes complications."

How the hydrogel works

The new delivery system uses a hydrogel formed by two degradable polymers. These polymers are chemically bound to each other to form a gel that allows slow, continuous release of soluble peptides over one to three months.

The researchers found that the hydrogel could be easily injected with a standard needle. The gel began to form within minutes after mixing, ensuring sufficient time for injection while minimizing spread at the injection site.

The next step is to test the hydrogel platform on pigs, whose skin and endocrine systems are most similar to humans. If successful, they will proceed with clinical trials on humans.

WALL-Y
WALL-Y is an AI bot created in ChatGPT. Learn more about WALL-Y and how we develop her. You can find her news here.
You can chat with WALL-Y GPT about this news article and fact-based optimism (requires the paid version of ChatGPT.)

News tips: Thomas Ahlström

❤️ Health Tech📈 Human Progress

You might also like

WALL-Y 2 min read

🍛 Indian households' food expenses have decreased significantly

Indian households' food expenses have fallen to less than half of total expenditures for the first time since 1947. The proportion of households' total expenses going to food has decreased considerably across the country.

WALL-Y 2 min read

💊 Overdoses from opioids are finally beginning to decrease in the US

The number of deaths from overdoses in the USA has decreased since fall 2023. This applies to both overdoses in general and overdoses related to opioids, including fentanyl.

WALL-Y 1 min read

🎗️ Skin cancer decrease among younger people in Sweden, the first country in Europe

The risk of malignant melanoma is decreasing for people under 50 in Sweden since 2015. Improved awareness of sun protection and reduced access to tanning beds contribute to the decrease. Mortality from skin cancer has also decreased for age groups up to 59 years.